Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CASP1 | P29466 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 4/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427266 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CASP1CYP3A4TSHRPDE10A | |
| SCHEMBL16121520 | 0.86 | ALDH1A1 (0.35) | ALDH1A1CASP1CYP3A4TSHRLPL | |
| SCHEMBL16121467 | 0.86 | ALDH1A1 (0.35) | ALDH1A1CASP1CYP3A4TSHR | |
| SCHEMBL58186 | 0.85 | ALDH1A1 (0.43) | ALDH1A1CASP1CYP3A4TSHRPDE10A | |
| SCHEMBL29407647 | 0.85 | ALDH1A1 (0.43) | ALDH1A1CASP1CYP3A4TSHRPDE10A | |
| SCHEMBL28601719 | 0.85 | LPL (0.36) | ALDH1A1CASP1LPLLIPGCA1 | |
| SCHEMBL29688166 | 0.81 | LPL (0.36) | ALDH1A1CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4827664 | 0.81 | LPL (0.36) | ALDH1A1CYP3A4KDM4ELMNASMN1; SMN2 | |
| SCHEMBL12481678 | 0.80 | CYP3A4 (0.42) | ALDH1A1CASP1CYP3A4TSHRMAPT | |
| SCHEMBL21543816 | 0.80 | LPL (0.33) | ALDH1A1KDM4EMAPTLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4727922-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727921-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4695231-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4598927-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250250235-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-08-07 | — | — | US | disclosed |
| US-20250206729-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | disclosed |
| WO-2025137105-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12319655-B2 | RAF kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2007138242-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138242-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319655-B2 | RAF kinase inhibitors and methods of use thereof | BRAF, RAF1, ARAF | ALDH1A1 2049/4885CASP1 3475/4885CYP3A4 4349/4885 |
| US-20250206729-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | BRAF, MAP2K2, MAP2K1 | ALDH1A1 2583/4885CASP1 3221/4885CYP3A4 4717/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | ALDH1A1 4156/4885CASP1 2431/4885CYP3A4 4740/4885 |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | ALDH1A1 4272/4885CASP1 307/4885CYP3A4 4262/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | ALDH1A1 4600/4885CASP1 2578/4885CYP3A4 4788/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | ALDH1A1 3824/4885CASP1 610/4885CYP3A4 4654/4885 |
| US-20250250235-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ALDH1A1 2049/4885CASP1 3475/4885CYP3A4 4349/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | ALDH1A1 1563/4885CASP1 680/4885CYP3A4 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.